Edwards Lifesciences Corporation $EW Shares Acquired by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. boosted its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 0.5% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,381,912 shares of the medical research company’s stock after buying an additional 6,576 shares during the period. Sumitomo Mitsui Trust Group Inc. owned 0.24% of Edwards Lifesciences worth $107,471,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in EW. Vanguard Group Inc. grew its stake in shares of Edwards Lifesciences by 1.2% in the second quarter. Vanguard Group Inc. now owns 69,997,629 shares of the medical research company’s stock valued at $5,474,515,000 after buying an additional 798,801 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Edwards Lifesciences by 0.4% during the 2nd quarter. Geode Capital Management LLC now owns 12,722,416 shares of the medical research company’s stock valued at $990,074,000 after acquiring an additional 45,555 shares in the last quarter. Jennison Associates LLC grew its holdings in shares of Edwards Lifesciences by 15.7% during the second quarter. Jennison Associates LLC now owns 11,670,991 shares of the medical research company’s stock valued at $912,788,000 after purchasing an additional 1,584,958 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its position in Edwards Lifesciences by 111.2% in the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company’s stock valued at $714,006,000 after purchasing an additional 4,805,819 shares during the last quarter. Finally, Ninety One UK Ltd grew its stake in shares of Edwards Lifesciences by 14.0% in the third quarter. Ninety One UK Ltd now owns 7,908,572 shares of the medical research company’s stock worth $615,050,000 after purchasing an additional 969,030 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on EW shares. Barclays restated an “overweight” rating and set a $104.00 price objective (up previously from $103.00) on shares of Edwards Lifesciences in a research report on Monday. Robert W. Baird set a $90.00 target price on Edwards Lifesciences in a research note on Monday. Truist Financial set a $92.00 price objective on Edwards Lifesciences and gave the company a “hold” rating in a research report on Friday, December 5th. UBS Group reissued a “neutral” rating and issued a $95.00 target price (up from $92.00) on shares of Edwards Lifesciences in a research report on Monday. Finally, Evercore ISI reissued an “outperform” rating and set a $94.00 price objective on shares of Edwards Lifesciences in a report on Monday, January 5th. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and an average target price of $94.87.

Edwards Lifesciences Stock Up 1.1%

NYSE:EW opened at $83.92 on Wednesday. The company has a market cap of $48.70 billion, a price-to-earnings ratio of 36.17, a P/E/G ratio of 3.33 and a beta of 0.95. Edwards Lifesciences Corporation has a 52-week low of $65.94 and a 52-week high of $87.89. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00. The stock’s fifty day moving average price is $85.05 and its two-hundred day moving average price is $80.46.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.08. The business had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The firm’s revenue was up 14.7% on a year-over-year basis. During the same period last year, the company earned $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. On average, analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insider Transactions at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 13,000 shares of the business’s stock in a transaction on Monday, November 10th. The stock was sold at an average price of $83.08, for a total value of $1,080,040.00. Following the completion of the sale, the chief financial officer directly owned 39,898 shares in the company, valued at $3,314,725.84. The trade was a 24.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Daniel J. Lippis sold 1,020 shares of the firm’s stock in a transaction on Monday, November 10th. The stock was sold at an average price of $82.55, for a total value of $84,201.00. Following the transaction, the vice president owned 22,002 shares in the company, valued at approximately $1,816,265.10. This trade represents a 4.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 57,824 shares of company stock worth $4,863,323 in the last three months. Insiders own 0.34% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.